Insider trade

CEO sold ~$383K of ARWR shares in the open market

Traded Jan 2, 2026 · Filed Jan 6, 2026

Why it stands out

The boss of Arrowhead Pharmaceuticals sold $383K of Arrowhead Pharmaceuticals shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

CEO$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$383,137

Shares × reported transaction price

Timing vs results

38 days after results of Nov 25, 2025, 34 days before results of Feb 5, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−7.4%	+0.3%	−7.7%
30 days	−8.7%	−2.0%	−6.7%
90 days	−13.7%	−4.8%	−8.9%
180 days	+22.2%	+8.6%	+13.6%

Past results only. Not a forecast.

Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
Partial disposition of shares to satisfy tax withholding obligations.
The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.21 to $66.58, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.